- BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.
- Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.
Novo Nordisk's CEO stepped down amidst market headwinds, leading to the end of the collaboration agreement with Hims & Hers Health.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk's CEO stepped down amidst market headwinds, leading to the end of the collaboration agreement with Hims & Hers Health.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.Also in this story
- Hims & Hers challenged Novo Nordisk's ruling regarding drug compounding.
- Novo Nordisk alleged Hims & Hers failed to adhere to law.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Hims & Hers Health
American telehealth company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock? Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, t